Table 1.
Demographic and baseline characteristics of patients
| Total N = 24 | |
|---|---|
| Sex, N (%) | |
| Male | 16 (66.7) |
| Female | 8 (33.3) |
| Median age, years (range) | 62 (36–77) |
| ECOG PS, N (%) | |
| 0 | 14 (58.3) |
| 1 | 10 (41.7) |
| Pathological diagnosis, N (%) | |
| Tubular adenocarcinoma | 21 (87.5) |
| Poorly differentiated adenocarcinoma | 1 (4.2) |
| Adenocarcinoma, NOS | 2 (8.3) |
| Location of primary lesion, N (%) | |
| Right‐sided colon | 4 (16.7) |
| Left‐sided colon | 6 (25.0) |
| Rectum | 14 (58.3) |
| Metastasis, N (%) | |
| Lung | 21 (87.5) |
| Lymph nodes | 18 (75.0) |
| Liver | 16 (66.7) |
| Peritoneal | 3 (12.5) |
| Bone | 1 (4.2) |
| Pleural | 1 (4.2) |
| Adrenal gland | 1 (4.2) |
| No. colorectal cancer chemotherapy regimens, N (%) | |
| ≤3 regimens | 7 (29.2) |
| >3 regimens | 17 (70.8) |
| Prior chemotherapy regimens/agents, N (%) | |
| Fluoropyrimidines | 24 (100) |
| Irinotecan | 24 (100) |
| Oxaliplatin | 24 (100) |
| Angiogenesis inhibitor | 21 (87.5) |
| Anti‐EGFR monoclonal antibody | 9 (37.5) |
| Regorafenib | 8 (33.3) |
| TAS‐102 | 4 (16.7) |
| Colorectal cancer surgical history, N (%) | |
| Yes | 21 (87.5) |
| No | 3 (12.5) |
| Colorectal cancer radiotherapy history, N (%) | |
| Yes | 7 (29.2) |
| No | 17 (70.8) |
Angiogenesis inhibitor, bevacizumab/ramucirumab; anti‐EGFR monoclonal antibody, cetuximab/panitumumab; ECOG PS, Eastern Cooperative Oncology Group Performance status; EGFR, epidermal growth factor receptor; NOS, not otherwise specified.